BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36787509)

  • 1. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden.
    Biondi M; Tettamanti S; Galimberti S; Cerina B; Tomasoni C; Piazza R; Donsante S; Bido S; Perriello VM; Broccoli V; Doni A; Dazzi F; Mantovani A; Dotti G; Biondi A; Pievani A; Serafini M
    Blood; 2023 May; 141(21):2587-2598. PubMed ID: 36787509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche.
    Alberti G; Arsuffi C; Pievani A; Salerno D; Mantegazza F; Dazzi F; Biondi A; Tettamanti S; Serafini M
    Front Immunol; 2023; 14():1192333. PubMed ID: 37304257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
    Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
    Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
    Rotiroti MC; Buracchi C; Arcangeli S; Galimberti S; Valsecchi MG; Perriello VM; Rasko T; Alberti G; Magnani CF; Cappuzzello C; Lundberg F; Pande A; Dastoli G; Introna M; Serafini M; Biagi E; Izsvák Z; Biondi A; Tettamanti S
    Mol Ther; 2020 Sep; 28(9):1974-1986. PubMed ID: 32526203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of CXCR4 in the pathogenesis of acute myeloid leukemia.
    Peled A; Tavor S
    Theranostics; 2013; 3(1):34-9. PubMed ID: 23382784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells.
    Nian Z; Zheng X; Dou Y; Du X; Zhou L; Fu B; Sun R; Tian Z; Wei H
    Clin Cancer Res; 2021 Nov; 27(21):6026-6038. PubMed ID: 34233960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
    Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
    PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
    Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M
    PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success.
    Michelozzi IM; Kirtsios E; Giustacchini A
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34198742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
    Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
    Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
    Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.
    Cho BS; Kim HJ; Konopleva M
    Korean J Intern Med; 2017 Mar; 32(2):248-257. PubMed ID: 28219003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?
    Bernasconi P; Farina M; Boni M; Dambruoso I; Calvello C
    Am J Hematol; 2016 May; 91(5):507-17. PubMed ID: 26822317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging.
    Duarte D; Amarteifio S; Ang H; Kong IY; Ruivo N; Pruessner G; Hawkins ED; Lo Celso C
    Immunol Cell Biol; 2019 Feb; 97(2):229-235. PubMed ID: 30422351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML.
    Perriello VM; Rotiroti MC; Pisani I; Galimberti S; Alberti G; Pianigiani G; Ciaurro V; Marra A; Sabino M; Tini V; Spinozzi G; Mezzasoma F; Morena F; Martino S; Salerno D; Ashby JF; Wingham B; Serafini M; Martelli MP; Falini B; Biondi A; Tettamanti S
    Blood Adv; 2023 Jun; 7(12):2855-2871. PubMed ID: 36521101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
    Albinger N; Pfeifer R; Nitsche M; Mertlitz S; Campe J; Stein K; Kreyenberg H; Schubert R; Quadflieg M; Schneider D; Kühn MWM; Penack O; Zhang C; Möker N; Ullrich E
    Blood Cancer J; 2022 Apr; 12(4):61. PubMed ID: 35418180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo isolation, expansion and bioengineering of CCR7+CD95-/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients' bone marrow.
    Cao H; Kim DH; Howard A; Moz H; Wasnik S; Baylink DJ; Chen CS; Reeves ME; Mirshahidi S; Xiao J; Francis O; Marcucci G; Xu Y
    Neoplasia; 2021 Dec; 23(12):1252-1260. PubMed ID: 34775232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
    Pizzitola I; Anjos-Afonso F; Rouault-Pierre K; Lassailly F; Tettamanti S; Spinelli O; Biondi A; Biagi E; Bonnet D
    Leukemia; 2014 Aug; 28(8):1596-605. PubMed ID: 24504024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bone marrow microenvironment - Home of the leukemic blasts.
    Shafat MS; Gnaneswaran B; Bowles KM; Rushworth SA
    Blood Rev; 2017 Sep; 31(5):277-286. PubMed ID: 28318761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.